Nurix Therapeutics (NRIX)
(Delayed Data from NSDQ)
$8.44 USD
-0.53 (-5.91%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $8.42 -0.02 (-0.24%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Nurix Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
NRIX 8.44 -0.53(-5.91%)
Will NRIX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NRIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NRIX
KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
NRIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 143.41% Upside in Nurix Therapeutics (NRIX): Here's What You Should Know
Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?
Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates
Other News for NRIX
Technical picture remains unchanged for NRIX after it falls 5.91% on September 20
NRIX forms Stochastic Buy Signal on September 18
Pocket Pivot appears for NRIX after 1.54% move
Nurix Therapeutics (NRIX) Receives a Buy from Stifel Nicolaus
Nurix Therapeutics (NRIX) Gets a Buy from Barclays